Comparison · NCT02898077-sae
8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel vs Placebo + 80 mg/m² Paclitaxel: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel vs Placebo + 80 mg/m² Paclitaxel: serious adverse events. Trial comparisons, record NCT02898077-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02898077-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.341 | 0.289 | 0.397 | wilson | |
| Risk in group 2 | 0.255 | 0.191 | 0.332 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0861 | -0.00645 | 0.171 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.34 | 0.971 | 1.84 | log | |
| Odds ratio, group 1 over group 2 | 1.51 | 0.97 | 2.36 | log | |
| Number needed to harm, for one more participant with a serious adverse event on 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel than on Placebo + 80 mg/m² Paclitaxel | 11.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | 8 mg/kg ramucirumab was administered as an IV on days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on days 1, 8, and 15 of every 28-day cycle.~Participants may continue on treatment until discontinuation criteria were met. | 100 | 293 | EG000 |
| Group 2 | Placebo + 80 mg/m² Paclitaxel | Placebo was administered at a volume equivalent to a dose of 8 mg/kg by IV on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on Days 1, 8, and 15 of a 28-day cycle.~Participants may continue on treatment until discontinuation criteria were met. | 37 | 145 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse Events: Randomization Up To 26 Months; All-Cause Mortality: Randomization to Date of Death from Any Cause (Up To 37 Months)
Source ClinicalTrials.gov
Trial
- Title
- A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
- NCT number
- NCT02898077
- Phases
- PHASE3
- Conditions
- Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
- Interventions
- Ramucirumab, Paclitaxel, Placebo
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2021-08-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02898077?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02898077-sae